Want to see HK:1276 full AI Analyst Report?
Top Page
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
(1276)
Select Model
Select Model
Rating:69Neutral
Price Target:
HK$53.00
▲(13.98% Upside)
Action:Reiterated
Date:08/24/26
The score is driven primarily by strong financial performance (high margins and very low leverage), but is meaningfully held back by weak technicals (below major moving averages with negative momentum) and a relatively high P/E that limits valuation support.
Positive Factors
Very high profitability
Exceptional gross and net margins provide a durable earnings base and indicate strong product economics. Sustaining these margins can support internal funding for pharmaceutical research, regulatory work, manufacturing capacity, and commercial expansion.
Negative Factors
Recent top-line softness
A decline in trailing revenue indicates that current commercial momentum is weaker despite strong margins. Persistent top-line softness could limit operating leverage, reduce funding for research, and increase dependence on successful launches or portfolio renewal.
Read all positive and negative factors
Positive Factors
Negative Factors
Very high profitability
Exceptional gross and net margins provide a durable earnings base and indicate strong product economics. Sustaining these margins can support internal funding for pharmaceutical research, regulatory work, manufacturing capacity, and commercial expansion.
Read all positive factors
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (1276) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$350.56B
Dividend Yield0.5%
Average Volume (3M)5.79M
Price to Earnings (P/E)37.9
Beta (1Y)0.55
Revenue Growth7.52%
EPS GrowthN/A
CountryHK
Employees20,602
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.32
Shares Outstanding258,197,600
10 Day Avg. Volume4,918,507
30 Day Avg. Volume5,790,772
Financial Highlights & Ratios
PEG Ratio2.21
Price to Book (P/B)6.79
Price to Sales (P/S)13.15
P/FCF Ratio50.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$83.05Price Target Upside78.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)1.61
Revenue Forecast (FY)HK$39.32B
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncolo...
How the Company Makes Money
The company primarily makes money by selling pharmaceutical products, generating revenue from the commercialization of its proprietary drug portfolio through distribution to hospitals, pharmacies, and other healthcare channels. A key revenue strea...
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
93
Very Positive
Cash Flow
74
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 35.06B | 35.19B | 29.77B | 25.26B | 24.23B | 31.02B |
| Gross Profit | 29.82B | 30.33B | 25.68B | 21.36B | 20.26B | 26.20B |
| EBITDA | 9.31B | 10.64B | 8.46B | 5.95B | 5.19B | 5.19B |
| Net Income | 8.68B | 8.58B | 6.74B | 4.76B | 4.45B | 5.46B |
Balance Sheet | ||||||
| Total Assets | 81.79B | 77.73B | 53.33B | 48.21B | 47.57B | 48.03B |
| Cash, Cash Equivalents and Short-Term Investments | 44.89B | 45.69B | 26.69B | 22.95B | 20.06B | 22.90B |
| Total Debt | 836.30M | 48.18M | 73.44M | 692.54M | 1.91B | 1.36B |
| Total Liabilities | 6.68B | 8.98B | 4.30B | 2.99B | 4.31B | 4.38B |
| Stockholders Equity | 74.51B | 68.17B | 48.42B | 44.55B | 42.47B | 42.82B |
Cash Flow | ||||||
| Free Cash Flow | 6.32B | 9.20B | 5.80B | 6.82B | -827.89M | 3.39B |
| Operating Cash Flow | 10.01B | 12.50B | 7.90B | 8.46B | 1.44B | 5.40B |
| Investing Cash Flow | -4.02B | -3.05B | -2.03B | 1.35B | 444.51M | -559.25M |
| Financing Cash Flow | -1.93B | 8.66B | -1.65B | -3.48B | -363.05M | -1.62B |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H Technical Analysis
Negative
46.50
Price Trends
70.43
Negative
71.84
Negative
Market Momentum
-1.57
Negative
43.88
Neutral
75.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1276, the sentiment is Negative. The current price of 46.5 is below the 20-day moving average (MA) of 66.77, below the 50-day MA of 70.43, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of -1.57 indicates Negative momentum. The RSI at 43.88 is Neutral, neither overbought nor oversold. The STOCH value of 75.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1276.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$218.79B | 27.06 | 18.26% | 1.24% | 24.97% | 43.23% | |
69 Neutral | HK$350.56B | 37.89 | 12.42% | 0.50% | 7.52% | ― | |
66 Neutral | HK$314.68B | 58.48 | 14.22% | ― | 34.73% | ― | |
63 Neutral | HK$104.08B | 36.08 | 7.56% | 2.14% | 14.57% | -31.09% | |
63 Neutral | HK$174.74B | 118.66 | 6.06% | ― | 42.64% | 9.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$88.61B | -78.18 | -10.86% | ― | 42.47% | -15.80% |
* Healthcare Sector Average
HK:1276
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
45.94
-36.87
-44.52%
HK:1177
Sino Biopharmaceutical
5.61
-2.63
-31.89%
HK:1801
Innovent Biologics
98.20
1.10
1.13%
HK:9926
Akeso, Inc.
95.05
-32.65
-25.57%
HK:3692
Hansoh Pharmaceutical Group Company Limited
34.80
0.05
0.16%
HK:6160
BeOne Medicines Ltd
208.60
14.80
7.64%
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H Corporate Events
Hengrui Pharma Wins NMPA Approval for Innovative PNH Drug
Aug 20, 2026
Jiangsu Hengrui Pharmaceuticals announced that its subsidiary Chengdu Suncadia Medicine has received marketing approval from China’s National Medical Products Administration for Licancopan Fumarate Capsules, a self-developed Class 1 innovati...
Hengrui Pharma Launches RMB1–2 Billion A-Share Buyback for Employee Ownership Plan
Aug 19, 2026
Jiangsu Hengrui Pharmaceuticals Co., Ltd. has announced a plan to repurchase its A shares on the Shanghai Stock Exchange through centralized price bidding, committing no less than RMB1 billion and no more than RMB2 billion of its own funds. The re...
Hengrui Pharma Advances 2026 Employee Stock Ownership Plan Using Existing A Shares
Aug 19, 2026
Jiangsu Hengrui Pharmaceuticals has approved a 2026 A share employee stock ownership scheme, which will take effect upon shareholder approval and will use existing A shares rather than issuing new equity or options. The programme aims to align the...
Jiangsu Hengrui Proposes 2026 H Share Incentive Scheme to Strengthen Governance
Aug 19, 2026
Jiangsu Hengrui Pharmaceuticals has proposed a new 2026 H Share Scheme that will grant restricted share units to directors, senior management and key personnel, subject to approval at an extraordinary shareholders’ meeting. The scheme is des...
Jiangsu Hengrui Pharmaceuticals Announces Resignation of Joint Company Secretary
Aug 19, 2026
Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced that joint company secretary Ms. Liu Xiaohan resigned with effect from August 19, 2026, with no disagreement with the board or issues requiring shareholder attention. Following her departure, the...
Jiangsu Hengrui Publishes Unaudited Interim Results for First Half of 2026
Aug 19, 2026
Jiangsu Hengrui Pharmaceuticals Co., Ltd., a Hong Kong-listed Chinese drug maker, specializes in developing and marketing pharmaceutical products for a broad healthcare market. The company operates as a regulated joint stock enterprise with a dive...
Hengrui Pharma Wins NMPA Nod for New Autoimmune Indication of Innovative Drug
Aug 6, 2026
Jiangsu Hengrui Pharmaceuticals has received approval from China’s National Medical Products Administration for a new indication of its self-developed Class 1 innovative drug, Ivarmacitinib Sulfate Tablets (SHR0302). The tablet, a 4 mg presc...
Hengrui Wins First-in-China Anti-HER2 Approval for Colorectal Cancer
Aug 6, 2026
Jiangsu Hengrui Pharmaceuticals has announced that its subsidiary Suzhou Suncadia Biopharmaceuticals received Chinese regulatory approval for a new indication of trastuzumab rezetecan for injection, classified as a Class 2.2 therapeutic biological...
Jiangsu Hengrui Board to Review Interim Results and Dividend in August
Aug 6, 2026
Jiangsu Hengrui Pharmaceuticals has scheduled a board meeting for August 19, 2026 to review and approve the interim financial results for the first half of 2026. The board will also consider the declaration of an interim dividend for the six month...
Hengrui Pharma Wins First China Approval for Home-Grown Long-Acting Insulin Analog
Jul 29, 2026
Jiangsu Hengrui Pharmaceuticals has obtained approval from China’s National Medical Products Administration to market insulin sudelidec injection, a Class 1 therapeutic biological product it independently developed. The drug is China’s...
Hengrui Wins NMPA Nod to Move Cervical Cancer Combo to First-Line Use
Jul 23, 2026
Jiangsu Hengrui Pharmaceuticals and its subsidiary Suzhou Suncadia Biopharmaceuticals have received approval from China’s National Medical Products Administration to market their innovative drug combo, camrelizumab for injection with famitin...
Hengrui Pharma Wins NMPA Approval for First 0.1% Water-Free Cyclosporine Eye Drop in China
Jun 25, 2026
Jiangsu Hengrui Pharmaceuticals announced that its subsidiary, Chengdu Suncadia Medicine, has received approval from China’s National Medical Products Administration to launch Cyclosporine Ophthalmic Solution (IV). The product is a 0.1% wate...
Hengrui Wins Landmark NMPA Nod for New Lung Cancer Use of PD-L1 Drug
Jun 25, 2026
Jiangsu Hengrui Pharmaceuticals announced that its subsidiary Shanghai Suncadia Medicine has received approval from China’s National Medical Products Administration for a new indication of adebrelimab injection. The drug, classified as a Cla...
Hengrui Pharma Wins NMPA Nod for New Dalpiciclib Breast Cancer Indication
Jun 16, 2026
Jiangsu Hengrui Pharmaceuticals has received approval from China’s National Medical Products Administration for a new indication of its self-developed CDK4/6 inhibitor, dalpiciclib isethionate tablets. The drug, in 50 mg and 125 mg tablet fo...
Hengrui Pharma Wins NMPA Approval for First Domestic New-Generation URAT1 Inhibitor
May 28, 2026
Jiangsu Hengrui Pharmaceuticals has obtained marketing approval from China’s National Medical Products Administration for its self-developed Class 1 innovative drug Ruzinurad Tablets (SHR4640), a highly selective new-generation URAT1 inhibit...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.